Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 11:59:58 2024-03-18 am EDT 5-day change 1st Jan Change
697.5 DKK 0.00% Intraday chart for Zealand Pharma A/S +1.68% +86.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle... Our Logo
Zealand Pharma A/S Announces Board Changes CI
Nordic Stocks Dropped Monday; Zealand Pharma Took Biggest Hit DJ
Nordic Stocks Moved Upward Thursday; Zealand Pharma Topped Leaders DJ
US Futures, European Stocks Mostly Down DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Transcript : Zealand Pharma A/S, 2023 Earnings Call, Feb 27, 2024
US Futures Flat, European Stocks Mostly Rise DJ
Zealand Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zealand Pharma Shares Surge 41% on 'Positive' Results From Phase 2 Study of Weight Loss Drug Survodutide MT
Nordic Shares Declined Monday; Embracer Group Series B Posted Biggest Loss DJ
European Equities Close Mostly Lower in Monday Trading; UK Regulator Probes Homebuilders for Anti-Competitive Practices MT
Boehringer eyes obesity, fatty liver drug launch in 2027 or 2028 RE
BOEHRINGER EXEC BROUILLON TELLS REUTERS IT IS NOT CLEAR YET WHET… RE
Zealand Pharma: positive results in NASH CF
Commodity-linked stocks drag European equities lower RE
Zealand shares surge on liver drug data from Boehringer pact RE
Zealand Pharma shares surge on liver disease drug trial data RE
US Futures, European Stocks Mostly Fall DJ
Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis CI
Nordic Shares Rose Monday; Vitrolife Topped Leaders DJ
Zealand Pharma, a new competitor for Novo Nordisk? Our Logo
Weight loss drug windfall attracts pharma companies RE
Drugmakers plot way into obesity market with deals and development RE
Nordic Stocks Decreased Tuesday; TGS Fell Furthest DJ
Chart Zealand Pharma A/S
More charts
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
697.5 DKK
Average target price
690.3 DKK
Spread / Average Target
-1.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
  4. News Zealand Pharma A/S
  5. Zealand Pharma Signs License Agreement With Novo Nordisk for Hypoglycemia Treatment